Oligonucleotide– tag –
-
Arbutus & Genevant Sue Federal Government for Patent Infringement on Moderna mRNA Vaccine LNP Components
Patent Docs United States Overview On September 11, 2026, Arbutus Biopharma and Genevant Sciences filed a patent infringement lawsuit against the U.S. Federal Government regarding the lipid nanoparticle (LNP) components used in Moderna’s... -
FDA Approves Vertex’s Zanvastro: First Disease-Modifying ASO Therapy for Alexander Disease
Healio USA Overview The U.S. FDA has approved Zanvastro (zilgannersen), an antisense oligonucleotide (ASO) therapy from Vertex Pharmaceuticals, for pediatric and adult patients with Alexander disease. This marks the first disease-modifyi... -
Google DeepMind’s AlphaFold 3 Achieves Unprecedented Accuracy in Predicting Molecular Interactions, Driving AI-Discovered Drugs to Phase III Trials
New Market Pitch Unknown Overview AI drug discovery is now fully functional in structural prediction, molecular design, lead optimization, and protein engineering. Google DeepMind and Isomorphic Labs' AlphaFold 3 demonstrates superior ac... -
Waterfall Scientific Wins Up to $54.5 Million from ARPA-H to Pioneer Continuous-Flow mRNA Manufacturing Platform
Pulse 2.0 USA Overview Waterfall Scientific has been awarded up to $54.5 million from ARPA-H to lead a consortium in developing the ESCALATOR project, a continuous-flow platform for mRNA manufacturing and characterization. This initiativ... -
Ionis’ Zanvastro (Zilganersen) Gains FDA Approval as First Disease-Modifying ASO Therapy for Alexander Disease
Fierce Pharma USA Overview Ionis Pharmaceuticals has received FDA approval for Zanvastro (zilganersen), an antisense oligonucleotide (ASO) therapy, as the first disease-modifying treatment for Alexander disease. Zanvastro operates by spe... -
Moderna’s RSV Vaccine mRESVIA® Receives FDA Approval as mRNA Therapeutics Advance in Non-Vaccine Applications
Facebook (Vaxcyte, Vivaldi Biosciences) USA Overview Moderna's RSV vaccine mRESVIA® gained FDA approval following Breakthrough Therapy Designation, reaffirming the power of mRNA technology in infectious disease prevention. Concurrently, ... -
Recorna and Starna Therapeutics Partner to Advance RNA Gene Editing for Lung Diseases Leveraging STAR LNP Technology
Insight, China's Pharmaceutical Industry China Overview Chinese firms Recorna Biotechnology and Starna Therapeutics have formed a strategic partnership to develop RNA gene editing therapeutics for lung diseases. The collaboration will le... -
Insitro Appoints Hideo Makimura as Chief Medical Officer to Accelerate Transition from AI Drug Discovery to Clinical-Stage Company
BioSpace USA Overview Insitro, a pioneer in AI drug discovery, announced the appointment of Hideo Makimura as Chief Medical Officer (CMO), signaling a strategic acceleration from an AI-driven discovery firm to a clinical-stage company. M... -
Novartis’ DM1 Therapeutic Delpacibart Etedesiran Fails to Meet Primary Endpoint in Phase III HARBOR Study
Novartis Switzerland Overview Novartis announced that its antibody-oligonucleotide conjugate (AOC) delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) did not achieve a statistically significant improvement in the pr... -
Ribo Life Science’s siRNA Therapeutic Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Insight, China's Pharmaceutical Industry China Overview Ribo Life Science's siRNA therapeutic, vortosiran (BD4059), has received European Medicines Agency (EMA) approval for a clinical trial aimed at stroke prevention in atrial fibrillat...
